WallStreetZenWallStreetZen

NASDAQ: SONN
Sonnet Biotherapeutics Holdings Inc Earnings & Revenue

SONN past revenue growth

How has SONN's revenue growth performed historically?
Company
-49.81%
Industry
169.3%
Market
17.86%
SONN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SONN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SONN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SONN earnings and revenue history

Current Revenue
$129.2k
Current Earnings
-$14.5M
Current Profit Margin
-11,193.3%

SONN Return on Equity

Current Company
-519.5%
Current Industry
-63.4%
Current Market
188%
SONN's Return on Equity (-519.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SONN announces earnings.

SONN Return on Assets

Current Company
-169.5%
Current Industry
3.2%
SONN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SONN Return on Capital Employed

Current Company
-538.83%
Current Industry
19.9%
SONN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SONN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SONN$129.18k-$14.38M-$14.46M-66.53%N/A
XBIO$2.54M-$4.13M-$4.13M+249.28%N/A
SNGX$839.36k-$7.74M-$6.14M-30.67%N/A
GTBP$0.00-$7.38M-$7.60MN/AN/A
HOTH$0.00-$9.62M-$9.62MN/AN/A

SONN earnings dates

Next earnings date
May 8, 2024

Sonnet Biotherapeutics Holdings Earnings & Revenue FAQ

What were SONN's earnings last quarter?

On Invalid Date, Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported Q4 2023 earnings per share (EPS) of -$0.31, up 98.24% year over year. Total Sonnet Biotherapeutics Holdings earnings for the quarter were -$1.17 million. In the same quarter last year, Sonnet Biotherapeutics Holdings's earnings per share (EPS) was -$17.62.

If you're new to stock investing, here's how to buy Sonnet Biotherapeutics Holdings stock.

What was SONN's earnings growth in the past year?

As of Q1 2024, Sonnet Biotherapeutics Holdings's earnings has grown year over year. Sonnet Biotherapeutics Holdings's earnings in the past year totalled -$14.46 million.

What is SONN's earnings date?

Sonnet Biotherapeutics Holdings's earnings date is Invalid Date. Add SONN to your watchlist to be reminded of SONN's next earnings announcement.

What was SONN's revenue last quarter?

On Invalid Date, Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported Q4 2023 revenue of $18.63 thousand up 50% year over year. In the same quarter last year, Sonnet Biotherapeutics Holdings's revenue was $37.26 thousand.

What was SONN's revenue growth in the past year?

As of Q1 2024, Sonnet Biotherapeutics Holdings's revenue has grown -49.81% year over year. This is 219.11 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Sonnet Biotherapeutics Holdings's revenue in the past year totalled $129.18 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.